Tuesday, January 16, 2018 10:01:52 AM
I think you're right in that the proxy language will be their justification. It is the most detailed and only language that addresses these issues.
From your links, it would appear that the Reverse Stock Split is not a routine matter, and therefore Brokers cannot vote on it without clear instructions from the stock owner. The Broker Non Votes could be used to establish a quorum, but could not be counted as votes "entitled" to be cast.
A review of the vote totals shows that 86,422,923 total votes were available for proposals 3 & 4. (BTW - if my math is correct - there were 86,422,925 total votes for every other item. Somehow proposals 3 & 4 lost 2 votes?!).
It is clear from proposals 1 and 2 that there were 50,828,832 Broker Non-Votes. If what I believe is true, these cannot be considered as eligible votes for proposal 3. That would leave 35,594,091 votes entitled to be cast for proposal 3.
In their proxy statement regarding proposal 3, they indicate that "an abstention will have the effect of a negative vote", i.e. they will count as eligible votes in the denominator of the calculation. If I understand correctly, the vote calculation for proposal 3 should be:
(Votes "For") / (Votes "For" + Votes "Against" + "Abstentions")
Subtracting the Broker non-votes from their "For" total gives a total of 12,034,890 actual votes cast "For". Votes "Against" were 22,661,563 and "Abstentions" 897,638.
Proposal 3 received 33.8% of the eligible votes by this method.
This is just my take on your links...I am not an attorney. Therefore...
Yes. We should contact Francis G.X. Pileggi this morning. If he's not available, we should try to find someone else in the firm who handles such matters. I'm happy to call and get this started. Or we can both make contact. As I stated in a previous post, I'm happy to share with you my contact info through their office to help us coordinate efforts if the attorney thinks this exercise has merit.
Let me know your thoughts.
Recent BPTH News
- Bio-Path Holdings Announces Publication in Biomedicines • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:10:15 PM
- Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:15:26 PM
- Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 11:30:23 AM
- Bio-Path Holdings Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:41:00 PM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:14:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:10:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:38:40 PM
- Bio-Path Holdings Provides Clinical Update and Expansion Plans • GlobeNewswire Inc. • 07/08/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/17/2024 12:00:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/17/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:18:17 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/11/2024 09:30:47 PM
- Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:20:35 PM
- Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM